These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 25031337)
21. Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants. Berro R; Yasmeen A; Abrol R; Trzaskowski B; Abi-Habib S; Grunbeck A; Lascano D; Goddard WA; Klasse PJ; Sakmar TP; Moore JP J Virol; 2013 Jun; 87(12):6569-81. PubMed ID: 23468486 [TBL] [Abstract][Full Text] [Related]
22. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865 [TBL] [Abstract][Full Text] [Related]
23. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Kramer VG; Schader SM; Oliveira M; Colby-Germinario SP; Donahue DA; Singhroy DN; Tressler R; Sloan RD; Wainberg MA Antimicrob Agents Chemother; 2012 Aug; 56(8):4154-60. PubMed ID: 22615275 [TBL] [Abstract][Full Text] [Related]
24. A high throughput Cre-lox activated viral membrane fusion assay identifies pharmacological inhibitors of HIV entry. Esposito AM; Cheung P; Swartz TH; Li H; Tsibane T; Durham ND; Basler CF; Felsenfeld DP; Chen BK Virology; 2016 Mar; 490():6-16. PubMed ID: 26803470 [TBL] [Abstract][Full Text] [Related]
25. HIV-1 requires Arf6-mediated membrane dynamics to efficiently enter and infect T lymphocytes. García-Expósito L; Barroso-González J; Puigdomènech I; Machado JD; Blanco J; Valenzuela-Fernández A Mol Biol Cell; 2011 Apr; 22(8):1148-66. PubMed ID: 21346189 [TBL] [Abstract][Full Text] [Related]
26. HIV-1 Entry and Membrane Fusion Inhibitors. Xiao T; Cai Y; Chen B Viruses; 2021 Apr; 13(5):. PubMed ID: 33922579 [TBL] [Abstract][Full Text] [Related]
27. Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. Kimpel J; Braun SE; Qiu G; Wong FE; Conolle M; Schmitz JE; Brendel C; Humeau LM; Dropulic B; Rossi JJ; Berger A; von Laer D; Johnson RP PLoS One; 2010 Aug; 5(8):e12357. PubMed ID: 20808813 [TBL] [Abstract][Full Text] [Related]
28. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. Platt EJ; Durnin JP; Kabat D J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435 [TBL] [Abstract][Full Text] [Related]
29. In vitro activities of candidate microbicides against cell-associated HIV. Selhorst P; Grupping K; Bourlet T; Delézay O; Ariën KK; Vanham G Antimicrob Agents Chemother; 2012 Feb; 56(2):805-15. PubMed ID: 22083472 [TBL] [Abstract][Full Text] [Related]
30. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition. Panos G; Watson DC Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642 [TBL] [Abstract][Full Text] [Related]
31. Differential regulation of CXCR4 and CCR5 expression by interleukin (IL)-4 and IL-13 is associated with inhibition of chemotaxis and human immunodeficiency Virus (HIV) type 1 replication but not HIV entry into human monocytes. Creery D; Weiss W; Graziani-Bowering G; Kumar R; Aziz Z; Angel JB; Kumar A Viral Immunol; 2006; 19(3):409-23. PubMed ID: 16987060 [TBL] [Abstract][Full Text] [Related]
32. Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors. Wu CH; Wang CJ; Chang CP; Cheng YC; Song JS; Jan JJ; Chou MC; Ke YY; Ma J; Wong YC; Hsieh TC; Tien YC; Gullen EA; Lo CF; Cheng CY; Liu YW; Sadani AA; Tsai CH; Hsieh HP; Tsou LK; Shia KS J Med Chem; 2015 Feb; 58(3):1452-65. PubMed ID: 25584630 [TBL] [Abstract][Full Text] [Related]
33. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. Lu L; Pan C; Li Y; Lu H; He W; Jiang S Retrovirology; 2012 Dec; 9():104. PubMed ID: 23217195 [TBL] [Abstract][Full Text] [Related]
34. A potential in vitro and in vivo anti-HIV drug screening system for Chinese herbal medicines. Feng L; Wang L; Ma YY; Li M; Zhao GQ Phytother Res; 2012 Jun; 26(6):899-907. PubMed ID: 22852142 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of HIV-1 entry by the tricyclic coumarin GUT-70 through the modification of membrane fluidity. Matsuda K; Hattori S; Kariya R; Komizu Y; Kudo E; Goto H; Taura M; Ueoka R; Kimura S; Okada S Biochem Biophys Res Commun; 2015 Feb; 457(3):288-94. PubMed ID: 25576356 [TBL] [Abstract][Full Text] [Related]
36. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists. Lin G; Bertolotti-Ciarlet A; Haggarty B; Romano J; Nolan KM; Leslie GJ; Jordan AP; Huang CC; Kwong PD; Doms RW; Hoxie JA J Virol; 2007 Sep; 81(18):9956-66. PubMed ID: 17609282 [TBL] [Abstract][Full Text] [Related]
37. HIV cell fusion assay: phenotypic screening tool for the identification of HIV entry inhibitors via CXCR4. Smith EB; Ogert RA; Pechter D; Villafania A; Abbondanzo SJ; Lin K; Rivera-Gines A; Rebsch-Mastykarz C; Monsma FJ J Biomol Screen; 2014 Jan; 19(1):108-18. PubMed ID: 23989454 [TBL] [Abstract][Full Text] [Related]
38. Purinergic receptors are required for HIV-1 infection of primary human macrophages. Hazleton JE; Berman JW; Eugenin EA J Immunol; 2012 May; 188(9):4488-95. PubMed ID: 22450808 [TBL] [Abstract][Full Text] [Related]
39. HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies. Mostashari Rad T; Saghaie L; Fassihi A Chem Biodivers; 2018 Oct; 15(10):e1800159. PubMed ID: 30027572 [TBL] [Abstract][Full Text] [Related]
40. Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetropic isolates of human immunodeficiency virus type 1. Lee S; Lapham CK; Chen H; King L; Manischewitz J; Romantseva T; Mostowski H; Stantchev TS; Broder CC; Golding H J Virol; 2000 Jun; 74(11):5016-23. PubMed ID: 10799575 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]